Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
By A. Ravaud, R. Motzer, H. Pandha, D. George, A. Pantuck, Anup Patel, Yen‐Hwa Chang, B. Escudier, F. Donskov, A. Magheli and 12 more. New England Journal of Medicine, 2016
685 citations recorded by the source corpus.
Subfields: Molecular Biology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/d6f79559bbdfd110c8ebef19366ea5ef852df707
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, background): “Adjuvant therapy Several RCTs of adjuvant sunitinib (S-TRAC, ASSURE), sorafenib (ASSURE) and pazopanib (PROTECT) have been reported [32-34].”
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Adjuvant therapy Several RCTs of adjuvant sunitinib (S-TRAC, ASSURE), sorafenib (ASSURE) and pazopanib (PROTECT) have been reported [32-34].”
- Treatment of renal cell carcinoma: Current status and future directions (2017, methodology): “4% (median daily dose, 1000 mg) in the ASSURE study, emphasizing the importance of dose intensity in the adjuvant setting.(46,48) Third, the benefit must be well balanced with tolerability.”
- Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “2 years in a double-blind phase III clinical trial (NCT00375674).(412) Pazopanib (Table 1) is an oral angiogenic inhibitor that primarily inhibits VEGFR-1 (IC50= 10 nM), VEGFR-2 (IC50= 30 nM), VEGFR-3 (IC50= 47 nM), PDGFR-α (IC50= 71 nM), PDGFR-β (IC50= 84 nM), and the stem-cell factor receptor c-Ki”